Arcus Biosciences, Inc. financial data

Symbol
RCUS on NYSE
Location
3928 Point Eden Way, Hayward, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Oct 28, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 446 % -11.5%
Return On Equity -68.2 % -49.5%
Return On Assets -31.3 % -39.9%
Operating Margin -156 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 108M shares +18%
Common Stock, Shares, Outstanding 107M shares +17%
Entity Public Float 825M USD -22.7%
Weighted Average Number of Shares Outstanding, Basic 107M shares +16.5%
Weighted Average Number of Shares Outstanding, Diluted 107M shares +16.5%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 240M USD -45.8%
Revenue from Contract with Customer, Excluding Assessed Tax 45M USD -14.3%
Research and Development Expense 503M USD +14.3%
General and Administrative Expense 112M USD -7.44%
Operating Income (Loss) -375M USD -17.9%
Nonoperating Income (Expense) 35M USD -28.6%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -340M USD -26.4%
Income Tax Expense (Benefit) 1M USD 0%
Net Income (Loss) Attributable to Parent -341M USD -26.3%
Earnings Per Share, Basic -3 USD/shares -10.5%
Earnings Per Share, Diluted -3 USD/shares -10.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 238M USD +18.4%
Assets, Current 857M USD -24%
Property, Plant and Equipment, Net 42M USD -12.5%
Operating Lease, Right-of-Use Asset 65M USD -29.3%
Other Assets, Noncurrent 65M USD -13.3%
Assets 974M USD -22.2%
Accounts Payable, Current 42M USD +223%
Employee-related Liabilities, Current 28M USD +3.7%
Contract with Customer, Liability, Current 52M USD -50.5%
Liabilities, Current 235M USD +9.3%
Contract with Customer, Liability, Noncurrent 53M USD -81.7%
Operating Lease, Liability, Noncurrent 99M USD -10%
Other Liabilities, Noncurrent 152M USD +11.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1M USD
Retained Earnings (Accumulated Deficit) -1.38B USD -32.9%
Stockholders' Equity Attributable to Parent 436M USD -22.8%
Liabilities and Equity 974M USD -22.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -132M USD -6500%
Net Cash Provided by (Used in) Financing Activities 142M USD -38%
Net Cash Provided by (Used in) Investing Activities 32M USD
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 107M shares +17%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 42M USD -27.6%
Deferred Tax Assets, Valuation Allowance 316M USD +35.6%
Deferred Tax Assets, Gross 330M USD +30.4%
Operating Lease, Liability 111M USD -8.26%
Payments to Acquire Property, Plant, and Equipment 1M USD -75%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -342M USD -28.6%
Lessee, Operating Lease, Liability, to be Paid 133M USD -10.7%
Property, Plant and Equipment, Gross 88M USD +7.32%
Operating Lease, Liability, Current 13M USD +18.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 18M USD +5.88%
Lessee, Operating Lease, Liability, to be Paid, Year One 17M USD 0%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 22M USD -21.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 18M USD +5.88%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 19M USD +46.2%
Lessee, Operating Lease, Liability, to be Paid, Year Four 19M USD +5.56%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 62M USD -19.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%